The new Neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng Prefilled Syringe Inj (satralizumab, Roche) and new PD-1 inhibitor immune-oncology drug ‘Jemperli Inj (dostarlimab, GSK) will be reimbursed in Korea from December 1st this year.

Also, the insurance price ceiling for Xeljanz Tab 5mg, for which reimbursement has been extended to cover ankylosing spondylitis, will be reduced.

According to industry sources on the 21st, Enspryng will be reimbursed through the expenditure cap type RSA, and Jemperli through the expenditure cap type and refund type RSA from December 1st.

The price ceilings set for the drugs are KRW 7,823,456/syringe for Enspryng and KRW 3,868